Elevation Oncology Past Earnings Performance

Past criteria checks 0/6

Elevation Oncology's earnings have been declining at an average annual rate of -20.9%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

-20.9%

Earnings growth rate

64.7%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-60.5%
Net Margin	n/a
Last Earnings Update	30 Sep 2024

Recent past performance updates

No updates

Recent updates

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Sep 25

Revenue & Expenses Breakdown

How Elevation Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ELEV Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	-42	15	27
30 Jun 24	-40	15	25
31 Mar 24	-39	14	24
31 Dec 23	-46	15	25
30 Sep 23	-57	16	35
30 Jun 23	-85	16	62
31 Mar 23	-95	16	72
31 Dec 22	-95	16	79
30 Sep 22	-86	15	70
30 Jun 22	-59	14	45
31 Mar 22	-44	11	33
31 Dec 21	-32	8	24
30 Sep 21	-31	6	26
30 Jun 21	-22	3	19
31 Mar 21	-20	2	18
31 Dec 20	-17	2	15

Quality Earnings: ELEV is currently unprofitable.

Growing Profit Margin: ELEV is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ELEV is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.

Accelerating Growth: Unable to compare ELEV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ELEV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).

Return on Equity

High ROE: ELEV has a negative Return on Equity (-60.48%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 07:59
End of Day Share Price	2025/01/03 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Elevation Oncology, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Swayampakula Ramakanth	H.C. Wainwright & Co.
Michael King	H.C. Wainwright & Co.
Silvan Tuerkcan	JMP Securities

Elevation Oncology Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

Elevation Oncology, Inc. Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-Expressing Solid Tumors

Elevation Oncology, Inc. Presents Preclinical Proof-Of-Concept Data Supporting Combination Potential of Eo-3021 with Vegfr2 or Pd-1 Inhibitors At Esmo Immuno-Oncology Annual Congress 2024

Price target decreased by 8.2% to US$7.50

Elevation Oncology Receives Non-Compliance Letter Regarding Nasdaq Minimum Bid Price Requirement

New minor risk - Market cap size

Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

Elevation Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Elevation Oncology, Inc., Annual General Meeting, Jun 13, 2024

Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors

Elevation Oncology: Rising On News, But Not The Time To Buy

Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021

New minor risk - Share price stability

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating E)-3021

Elevation Oncology, Inc Appoints Joseph J. Ferra, Jr. as Chief Executive Officer

New major risk - Financial position

New major risk - Shareholder dilution

Elevation Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $50.062056 million.

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Price target increased by 24% to US$6.00

Advisor notifies of intention to sell stock

Advisor notifies of intention to sell stock

Price target decreased by 19% to US$4.17

Elevation Oncology, Inc. Announces Management Changes

Price target decreased to US$5.17

Elevation Oncology GAAP EPS of -$0.86 misses by $0.07

Elevation Oncology secured $50M loan facility with K2 HealthVentures

Now 36% undervalued after recent price drop

Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022

We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely

Elevation Oncology, Inc. Appoints David Dornan as Chief Scientific Officer

Elevation Oncology, Inc., Annual General Meeting, Jun 17, 2022

Elevation Oncology, Inc. Announces Initial Data from Phase 2 CRESTONE Study of Seribantumab Selected for Oral Presentation at ASCO 2022

Less than half of directors are independent

We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate